drugset / Trial / NCT02293590
RICE: Remission by Intra-articular Injection Plus CErtolizumab
RandomizedParallel-groupOpen-labelTreatment
Summary
Tight control of an adaptive concomitant treatment strategy after initiation of CZP will lead to an improved outcome of RA patients with an active disease despite DMARD treatment.
Timeline
- Start
- 2013-11
- Primary completion
- 2017-12-22
- Completion
- 2018-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 200 mg | — |